Sagimet Biosciences Inc. has announced a global, exclusive license agreement with TAPI Technology & API Services (TAPI), a subsidiary of Teva Pharmaceutical Industries Ltd. Under the agreement, Sagimet will have access to innovative forms of resmetirom active pharmaceutical ingredient (API) developed by TAPI, which are covered by TAPI patent applications. The collaboration will support Sagimet's fixed-dose combination (FDC) program that combines denifanstat and resmetirom, with a Phase 1 pharmacokinetic trial underway and topline data expected by the end of 2025. Sagimet plans to select one of the licensed resmetirom forms for further development in a Phase 3 FDC tablet targeting cirrhosis of the liver, an area with high medical need and currently no approved therapies.